(NP (NP (NN Evaluation)) (PP (IN of) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP-COOD (NP (NN ligand)) (CC and) (NP (JJ thermal) (NN activation))) (PP (IN of) (NP (NP (JJ specific) (NN DNA) (NN binding)) (PP (IN by) (NP (ADJP (ADVP (FW in) (FW vitro)) (VBN synthesized)) (JJ human) (NN glucocorticoid) (NN receptor))))))))) (. .))
(S (NP-SBJ-28 (PRP We)) (VP (VBP have) (VP (VBN used) (NP (DT a) (JJ (immunoprecipitation DNA-binding)) (NN assay)) (S (NP-SBJ (-NONE- *-28)) (VP (TO to) (VP (VB analyze) (NP (NP (DT the) (NN capacity) (S (-NONE- *ICH*-102))) (PP (IN of) (NP (NP (NP (JJ human) (NN glucocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN hGR)) (-RRB- -RRB-))) (, ,) (VP (VBN generated) (NP (-NONE- *)) (PP (IN in) (NP (NN rabbit) (NN reticulocyte) (NNS lysates)))))) (, ,)) (S-102 (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB bind) (NP (NN DNA)))))))))) (. .))
(S (NP-SBJ (ADJP (ADVP (FW In) (FW vitro)) (VBN translated)) (NN hGR)) (VP (VBD was) (ADJP-PRD (JJ indistinguishable) (PP (IN from) (NP (JJ native) (NN hGR)))) (, ,) (SBAR (IN as) (S (NP-SBJ-30 (-NONE- *)) (VP (VBN determined) (NP (-NONE- *-30)) (PP (IN by) (NP-LGS-COOD (NP (NP (NN migration)) (PP (IN on) (NP (ADJP (NN sodium) (NN dodecyl) (JJ sulfate-polyacrylamide)) (NNS gels)))) (, ,) (NP (NP (NN sedimentation)) (PP (IN on) (NP (NN sucrose) (NN density) (NNS gradients)))) (, ,) (CC and) (NP (NP (NN reactivity)) (PP (IN with) (NP (NP (JJ antipeptide) (NNS antibodies)) (VP (VBN generated) (NP (-NONE- *)) (PP (IN against) (NP (NN hGR))))))))))))) (. .))
(S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (JJ cell-free) (VBN synthesized) (NN hGR)) (VP (VBD was) (ADJP-PRD (JJ capable) (PP (IN of) (NP (NP (JJ specific) (NN binding)) (PP (TO to) (NP (ADJP (NN glucocorticoid) (NN response) (NN element) (-LRB- -LRB-) (NN GRE) (-RRB- -RRB-) (JJ -containing)) (NN DNA) (NNS fragments))))))) (. .))
(S (S-ADV (NP-SBJ (-NONE- *-31)) (VP (VBG Using) (NP (DT this) (NN assay) (NN system)))) (, ,) (NP-SBJ-31 (PRP we)) (VP (VBP have) (VP (VBN evaluated) (NP (NP (DT the) (NNS contributions)) (PP (IN of) (NP-COOD (NP (NN ligand) (NN binding)) (CC and) (NP (NN heat) (NN activation)))) (PP (TO to) (NP (NP (NN DNA) (NN binding)) (PP (IN by) (NP (DT these) (NN glucocorticoid) (NNS receptors)))))))) (. .))
(S (NP-SBJ (ADJP (ADVP (FW In) (FW vitro)) (VBN translated)) (NN hGR)) (VP (VBD was) (ADJP-PRD (JJ capable) (PP (IN of) (NP (JJ selective) (NN DNA) (NN binding))) (PP (RB even) (IN in) (DT the) (NN absence) (IN of) (NP (NN glucocorticoid))))) (. .))
(S (NP-SBJ (NP (NN Treatment)) (PP (IN with) (NP-COOD (NP (NN dexamethasone)) (CC or) (NP (DT the) (JJ antiglucocorticoid) (NN RU486))))) (VP (VBD had) (NP (DT no) (JJ additional) (NN effect)) (PP (IN on) (NP (DT the) (JJ DNA-binding) (NN capacity))) (SBAR-TMP (WHADVP-32 (WRB when)) (S (NP-SBJ-33 (NN receptor) (NNS preparations)) (VP (VBD were) (VP (VBN maintained) (NP (-NONE- *-33)) (ADVP (-NONE- *T*-32)) (PP (IN at) (NP (NP (CD 0) (NN C)) (PRN (-LRB- -LRB-) (NP (DT no) (NN activation)) (-RRB- -RRB-))))))))) (. .))
(S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NN addition)) (PP (IN of) (NP-COOD (CC either) (NP (NN ligand)) (CC or) (NP (NN antagonist)))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (DT a) (NN heat) (NN activation) (NN step)))))) (VP (VBD promoted) (NP (NN DNA) (NN binding)) (PP (IN by) (NP (NP (RB approximately) (RB 3-fold)) (PP (IN over) (NP (NP (DT that)) (PP (IN of) (NP (JJ heat-activated) (JJ unliganded) (NNS receptors)))))))) (. .))
(S (NP-SBJ-34 (NP (NN Agonist)) (PRN (-LRB- -LRB-) (NP (NN dexamethasone)) (-RRB- -RRB-))) (VP (VBD was) (ADJP-PRD (ADJP (ADVP (RB slightly) (JJR more)) (JJ effective)) (PP (-NONE- *ICH*-103))) (PP (IN in) (S (NP-SBJ (-NONE- *-34)) (VP (VBG supporting) (NP (JJ specific) (NN DNA) (NN binding))))) (PP-103 (IN than) (NP (NP (NN antagonist)) (PRN (-LRB- -LRB-) (NP (NN RU486)) (-RRB- -RRB-))))) (. .))
(S (NP-SBJ-35 (NP (NN DNA) (NN binding)) (PP (IN by) (NP (ADJP (ADVP (FW in) (FW vitro)) (VBN synthesized)) (NN GR)))) (VP (VBD was) (VP (VBN blocked) (NP (-NONE- *-35)) (PP (IN by) (NP-LGS (NP (DT the) (NN addition)) (PP (IN of) (NP (NN sodium) (NN molybdate))) (PP (TO to) (NP (DT the) (NN receptor) (NNS preparations))) (PP-TMP (IN before) (NP-COOD (NP (NN steroid) (NN addition)) (CC and) (NP (JJ thermal) (NN activation)))))))) (. .))
(S (NP-SBJ (NP (NN Addition)) (PP (IN of) (NP (NN KCl)))) (VP (VBD resulted) (PP (IN in) (NP (RBR less) (NN DNA) (NN binding))) (PP (CC either) (JJ due) (TO to) (NP-COOD (NP (NP (NN blockage)) (PP (IN of) (NP (JJ DNA-receptor) (NN complex) (NN formation)))) (CC or) (NP (NP (NN disruption)) (PP (IN of) (NP (DT the) (NNS complexes))))))) (. .))
(S (NP-SBJ-37 (NP (DT The) (NN specificity)) (PP (IN of) (NP (NP (NN DNA) (NN binding)) (PP (IN by) (NP (JJ cell-free) (VBN synthesized) (NN hGR)))))) (VP (VBD was) (VP (VBN analyzed) (NP (-NONE- *-37)) (ADVP (RB further)) (PP (IN by) (S (NP-SBJ (-NONE- *)) (VP (VBG examining) (NP (NP (NP (DT the) (NNS abilities) (S (-NONE- *ICH*-38))) (PP (IN of) (NP (JJ various) (NNS DNAs)))) (S-38 (NP-SBJ-104 (-NONE- *)) (VP (TO to) (VP (VB compete) (PP (IN for) (S (NP-SBJ (-NONE- *-104)) (VP (VBG binding) (PP (TO to) (NP (NP (DT a) (ADJP (RB naturally) (VBG occurring)) (NN GRE)) (VP (VBD found) (NP (-NONE- *)) (PP (IN in) (NP (DT the) (ADJP (NN mouse) (JJ mammary) (NN tumor) (JJ virus-long) (JJ terminal)) (NN repeat)))))))))))))))))) (. .))
(S-COOD (S-COOD (S (NP-SBJ (NP (NNS Oligonucleotides)) (VP (VBG containing) (NP (DT the) (NN consensus) (NN GRE)))) (VP (VBD were) (NP-PRD (DT the) (ADJP (RBS most) (JJ efficient)) (NNS competitors)))) (, ,) (CC and) (S (NP-SBJ (NP (NNS fragments)) (VP (VBG containing) (NP (NP (JJ regulatory) (NNS sequences)) (PP (IN from) (NP (JJ glucocorticoid-repressible) (NNS genes)))))) (VP (VBD were) (ADJP-PRD (RB somewhat) (JJ competitive))))) (, ,) (IN whereas) (S (NP-SBJ-39 (ADJP (JJ single) (JJ stranded)) (NNS oligonucleotides)) (VP (VBD were) (ADJP-PRD (JJ unable) (S (NP-SBJ (-NONE- *-39)) (VP (TO to) (VP (VB compete) (PP (IN for) (NP (ADJP (NN mouse) (JJ mammary) (NN tumor) (JJ virus-long) (JJ terminal) (NN repeat)) (NN DNA) (NN binding))))))) (, ,) (PP (IN except) (SBAR-TMP (WHADVP-40 (WRB when)) (S (NP-SBJ (NN competitor)) (VP (VBD was) (ADJP-PRD (JJ present)) (PP (IN at) (NP (ADJP (RB extremely) (JJ high)) (NNS concentrations))) (ADVP (-NONE- *T*-40)))))))) (. .))
(S (ADVP (RB Together)) (NP-SBJ (DT these) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (NN hGR)) (VP (VBN synthesized) (NP (-NONE- *)) (PP (IN in) (NP (NN rabbit) (NN reticulocyte) (NNS lysates))))) (VP (VBZ displays) (NP (NP (JJ many)) (PP (IN of) (NP (NP (DT the) (JJ same) (NNS properties)) (, ,) (PP (VBG including) (NP (JJ GRE-specific) (NN DNA) (NN binding))) (, ,) (VP (VBN observed) (NP (-NONE- *)) (PP (IN for) (NP (NP (NN glucocorticoid) (NN receptor)) (ADJP (JJ present) (PP (IN in) (NP (NP (JJ cytosolic) (NNS extracts)) (PP (IN of) (NP (JJ mammalian) (NP-COOD (NP (NNS cells)) (CC and) (NP (NNS tissues)))))))))))))))))) (. .))
(S (NP-SBJ (NP (NNS Similarities)) (PP (IN between) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP-COOD (NP (NN dexamethasone)) (CC and) (NP (NN RU486))))))) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ antiglucocorticoid) (NNS properties)) (PP (IN of) (NP (NN RU486)))) (VP (VBP do) (RB not) (VP (VB occur) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ specific) (NN DNA) (NN binding)))))))))) (. .))
